Company intelligence / Profile preview
Avacta
London, United Kingdomavacta.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Avacta’s lead program, AVA6000—a FAP-enabled peptide-drug conjugate form of doxorubicin—has completed Phase Ia studies. It demonstrated a dramatic improvement in safety and tolerability compared to conventional doxorubicin. Multiple ongoing and durable RECIST responses have been observed in patients with high FAP expression or sensitivity to doxorubicin. Released drug concentrations were significant even in tumors with low FAP activity or stroma-only expression, indicating broad applicability within solid tumors. The company’s pipeline leverages its proprietary pre|CISION® and Affimer® platforms for targeted cancer therapy delivery.
- Therapeutic areas
- Oncology
- Modalities
- Peptide Drug Conjugates (PDC)Affimer® Drug Conjugates (AffDC)Protein scaffolds (Affimer technology)Small molecules (e.g., doxorubicin conjugates)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Daewoong Pharmaceutical – joint venture for immunotherapy/cell & gene therapies using Affimers.
Beyond the preview
Go deeper on Avacta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avacta.